Understanding Sleep and Early Life Adversity in Young Adults
This study, called "The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies," aims to understand how disrupted sleep connects adverse childhood experiences (ACEs) with changes in blood vessel function (vascular endothelial dysfunction). Researchers will use Cognitive Behavioral Therapy for Insomnia (CBT-i), a structured program to improve sleep, as an intervention. The study is looking for 70 young adults, aged 18 to 29, who meet specific blood pressure and body mass index requirements. The main goal is to see how CBT-i affects blood vessel function, measured at the start and after 7 weeks. This research will help us understand how sleep can impact health in young adults who have experienced early life adversity.
- Study design
- This interventional study plans to enroll 70 participants. It uses a cross-sectional cohort design to understand the relationship between sleep, early life adversity, and vascular health.
- What's involved
- You would complete in-home sleep studies and participate in Cognitive Behavioral Therapy for Insomnia (CBT-i). Vascular endothelial function will be measured at the beginning and after 7 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants are followed for 7 weeks, with measurements taken at the start and end of this period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Nathaniel Jenkins, PhD · PRINCIPAL_INVESTIGATOR · Assistant Professor
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Vascular Endothelial FunctionWeek 0 (Pre-Intervention) and Week 7 (Post-Intervention)
The brachial artery flow-mediated dilation (FMD) technique, a non-invasive bioassay of endothelium-dependent vasodilatory function, will be used as the primary determinant of in-vivo vascular endothelial function.